482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Deucravacitinib Prostate Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Dgpr1008 Prostate Cancer	Zhu Yinjie	P2	CC (46)
Epigallocatechin-3-Gallate Prostate Cancer	H. Lee Moffitt Cancer Center and Research Institute	P2	CC (46)
Etrumadenant Prostate Cancer	Coherus Oncology, Inc.	P2	CC (46)
Fezolinetant Prostate Cancer	Chinese University of Hong Kong	P2	CC (46)
Galunisertib Prostate Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CC (46)
Glycyrrhizic Acid Prostate Cancer	University of Illinois at Chicago	P2	CC (46)
Gnrh Prostate Cancer	Royal College of Surgeons, Ireland	P2	CC (46)
her3-dxd Prostate Cancer	Daiichi Sankyo	P2	CC (46)
hs-20093 for Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	CC (46)
Interferon Alfa-2B Prostate Cancer	Roswell Park Cancer Institute	P2	CC (46)
Mag-Epa Prostate Cancer	CHU de Quebec-Universite Laval	P2	CC (46)
Mcs® Prostate Cancer	Health Ever Bio-Tech Co., Ltd.	P2	CC (46)
Methylphenidate Prostate Cancer	M.D. Anderson Cancer Center	P2	CC (46)
Ocifisertib Prostate Cancer	Canadian Cancer Trials Group	P2	CC (46)
pds01adc Prostate Cancer	National Cancer Institute (NCI)	P2	CC (46)
Pegargiminase Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (46)
Retlirafusp Alfa Prostate Cancer	Fudan University	P2	CC (46)
Sacituzumab Tirumotecan Prostate Cancer	Virginia Commonwealth University	P2	CC (46)
srf617 Prostate Cancer	Coherus Oncology, Inc.	P2	CC (46)
Stravix Lyopreserved Placental Tissue Prostate Cancer	Johns Hopkins University	P2	CC (46)
Tinengotinib Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CC (46)
Tocilizumab Prostate Cancer	David Oh	P2	CC (46)
Trastuzumab Deruxtecan Prostate Cancer	AstraZeneca	P2	CC (46)
Utomilumab Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (46)
Volitinib Prostate Cancer	Canadian Cancer Trials Group	P2	CC (46)
Zimberelimab Prostate Cancer	Coherus Oncology, Inc.	P2	CC (46)
Adavosertib Prostate Cancer	Canadian Cancer Trials Group	P2	CC (45)
Gdc-1261 Prostate Cancer	Genentech, Inc.	P1/2	CC (45)
Hrs-4357 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (45)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Nezastomig Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Recombinant Ephb4-Hsa Fusion Protein Prostate Cancer	Northwestern University	P2	CC (45)
Shr-4394 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (45)
Bicarbonate Ion Prostate Cancer	University of Washington	P1/2	CC (44)
Fdht F-18 Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1	CC (44)
11C-YJH08 Prostate Cancer	Rahul Aggarwal	P1	CC (43)
[177lu]lu-psma-xt Prostate Cancer	Jinming Zhang	P1	CC (43)
18f-trx Prostate Cancer	Rahul Aggarwal	P1	CC (43)
Adxs-504 Prostate Cancer	Mark Stein	P1	CC (43)
Atv-1601 Prostate Cancer	Atavistik Bio, Inc	P1	CC (43)
Autologous Anti-Psca-Car-4-1Bb/Tcrzeta-Cd19T-Expressing T-Lymphocytes Prostate Cancer	City of Hope Medical Center	P1	CC (43)
Bendamustine Prostate Cancer	Fred Hutchinson Cancer Center	P1	CC (43)
CC-1 Prostate Cancer	University Hospital Tuebingen	P1	CC (43)
Cedazuridine Prostate Cancer	Roswell Park Cancer Institute	P1	CC (43)
Etb-Dualnk-01 Prostate Cancer	Beijing Biotech	P1	CC (43)
Immunoglobulin (H-Gamma1_L-Kappa)_Scfvkh-G1(H-Ch2-Ch3), Anti-[Homo Sapiens Klk2 (Kallikrein-2, Kallikrein Related Peptidase 2, Kallikrein 2 Prostatic) And Anti-[Homo Sapiens Cd3E (Cd3 Epsilon, Leu-4)], Homo Sapiens And Humanized Monoclonal Antibody, Bispecific, Bivalent Prostate Cancer	Janssen Research & Development, LLC	P1	CC (43)
Jnj-101556143 Prostate Cancer	Janssen Research & Development, LLC	P1	CC (43)
Ktx-2001 Prostate Cancer	K36 Therapeutics, Inc.	P1	CC (43)
Masofaniten Prostate Cancer	Pedro Barata, MD, MSc	P2	CC (43)

Showing 251 to 300 of 482 assets

PreviousPage 6 of 10Next